Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALVAC-HIV vCP205 +/- SF-2 rgp120 in HIV-uninfected adults
NCT00000871Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ALVAC-HIV and SF-2 gp120 in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Safety and Immunogenicity. Status: completed.
02
Drugs
ALVAC-HIVSF-2 gp120
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00000871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000871.